Time will tell: Community acceptability of HIV vaccine research before and after the “Step Study” vaccine discontinuation

Open Access Journal of Clinical Trials

Volumn 2, Issue , 2010, Pages 149-156

  Frew, Paula M ^a,b,c,d   Mulligan, Mark J ^a,b,c   Hou, Su I ^e   Chan, Kayshin ^c   del Rio, Carlos ^a,b,c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY CENTER FOR AIDS RESEARCH   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF GEORGIA   (United States)

Author keywords

AIDS; Community engagement; Men who have sex with men; Recruitment; Willingness to participate

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; ATTITUDE TO HEALTH; COMMUNITY CARE; CROSS-SECTIONAL STUDY; DRUG RESEARCH; DRUG SAFETY; FEMALE; HEALTH BELIEF; HUMAN; INTERNAL CONSISTENCY; MALE; MEN WHO HAVE SEX WITH MEN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PSYCHOMETRY; QUESTIONNAIRE; SOCIAL ACCEPTANCE;

EID: 78650519180     PISSN: None     EISSN: 11791519     Source Type: Journal    
DOI: 10.2147/OAJCT.S11915     Document Type: Article

References (38)

1. Buchbinder S, Mehrotra D, Duerr A, et al. The Step Study: a test-of-concept HIV vaccine efficacy trial. Lancet. 2008;372(9653):1881-1893.
2. Merck/HIV Vaccine Trials Network. Merck's Investigational HIV/AIDS Vaccine Candidate Advances To Phase II Efficacy Testing in Collaborative Clinical Trial. Jan 24, 2005. Available from http://www.hvtn.org/media/ press_releases.sht?id=41. Accessed on Aug 30, 2010.
3. Frew PM, del Rio C, Lu L, Clifton S, Mulligan M. Understanding differences in enrollment in a Phase IIb HIV vaccine trial among highrisk populations. J Acquir Immune Defic Syndr. 2009;50(3):314-319.
4. AIDS Vaccine Advocacy Coalition (AVAC). AVAC report 2008: the search must continue. New York: AVAC; 2008.
5. Merck/HVTN. Vaccination and enrollment are discontinued in phase II trials of Merck's investigational HIV vaccine candidate: interim analysis of STEP Study shows vaccine was not effective. 2007. Available from: http://www.hvtn.org/pdf/FINAL_HIV_Vaccine_Press_Release.pdf. Accessed Sep 22, 2007.
6. Chase M, Schoofs M. AIDS effort suffers big blow as Merck vaccine fails. Wall Street Journal. 2007 Sep 22:A2.
7. South African AIDS Vaccine Initiative (SAAVI). Vaccinations and enrollment are on hold in Phambili. 2007. Available from: http://www. saavi.org.za/6press2007.htm
8. South African AIDS Vaccine Initiative (SAAVI). Phambili trial-factsheet from the South African AIDS Vaccine Initiative. 2007. Available from: http://209.85.215.104/search?q/cache:xojh2XzWPnYJ:www.hvtn.org/ media/pr/PhambiliSAAVIstatement.pdf/phambilipstudy&hlsen&ctecln k&cdk5&gl5us.
9. Altman LK, Pollack A. Failure of vaccine test is setback in AIDS fight. New York Times. 2007 Sep 22:A8.
10. British Broadcasting Company (BBC). Merck abandons HIV vaccine trials 2007. Available from: http://news.bbc.co.uk/1/hi/health/7007734. stm. Accessed Sep 22, 2007.
11. Bagby D. Failed HIV vaccine study disappoints local participants: more than 100 volunteers joined research at Hope Clinic. Southern Voice. 2007 Sept 28.
12. Schafer M. Long shot: Emory's 'Week of Hope' raises funds for HIV vaccine research after year of setbacks. Southern Voice. 2008 May 9.
13. Bagby D. Investigators still seek answers in failed HIV vaccine study: higher rates of HIV in vaccine group may be related to cold virus immunity. Southern Voice. 2007 Nov 16.
14. Mulligan M, Curran J, Hunter E, Del Rio C. Vaccine search is vital in HIV/AIDS arsenal. Atlanta Journal-Constitution., 2008 Apr 10:A.
15. Frew PM, del Rio C, Clifton S, Archibald M, Hormes J, Mulligan MJ. Factors influencing HIV vaccine community engagement in the urban South. J Community Health. 2008;33(4):259-269.
16. Frew PM, Archibald M, Diallo DD, et al. An extended model of reasoned action to understand the influence of individual- and network- level factors on African Americans' participation in HIV vaccine research. Prev Sci. 2010;11(2):207-218.
17. Frew PM, Archibald M, Martinez N, del Rio C, Mulligan M. Promoting HIV vaccine research in the African American community: does the theory of reasoned action explain potential outcomes of involvement? Challenge: J Morehouse Res Inst. 2008;13(1):61-97.
18. Mills E, Nixon S, Singh S, Dolma S, Nayyar A, Kapoor S. Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge. PLoS Med. 2006;3(3):E94.
19. Brown-Peterside P, Chiasson MA, Ren L, Koblin BA. Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City. J Urban Health. 2000;77(3): 425-437.
20. Scheer S, Douglas JM Jr, Vittinghoff E, et al. Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 1999;20(2):172-178.
21. Djomand G, Katzman J, di Tommaso D, et al. Enrollment of racial/ ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Rep. 2005;120(5): 543-548.
22. Hays RB, Kegeles SM. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. J Acquir Immune Defic Syndr. 1999;20(2):164-171.
23. Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a Preventive HIV Vaccine Trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36(1):604-612.
24. Muhib F, Lin L, Stueve A, et al. A venue-based method for sampling hard-to-reach populations. Public Health Rep. 2001;116 Suppl 1: 216-222.
25. Salazar LF, Holtgrave DR, Crosby RA, Frew PM, Peterson JL. Issues related to gay and bisexual men's acceptance of a future AIDS vaccine. Int J STD AIDS. 2005;16:546-548.
26. Crosby RA, Holtgrave DR, Bryant L, Frew PM. Factors associated with the acceptance of an AIDS vaccine: an exploratory study. Prev Med. 2004;39(4):804-808.
27. Crosby RA, Holtgrave DR, Bryant L, Frew PM. Correlates of negative intent to receive an AIDS vaccine: an exploratory study. Int J STD AIDS. 2004;15:552-557.
28. Frew P, Hou S, Davis M, et al. The likelihood of participation in clinical trials can be measured: the Clinical Research Involvement Scales. J Clin Epidemiol. In press 2010.
29. Fishbein M, Triandis HC, Kanfer FH, Becker M, Middlestadt SE, Eichler A. Factors influencing behavior and behavior change. In: Baum A, Revenson TA, Singer J, editors. Handbook of Health Psychology. Mahwah, New Jersey: Lawrence Erlbaum Associates; 2001:3-14.
30. Colfax G, Buchbinder SP, Vamshidar G, et al. Motivations for participating in an HIV Vaccine Efficacy Trial. J Acquir Immune Defic Syndr. 2005;39(3):359-364.
31. Fuchs J, Durham M, McLellan-Lemal E, et al. Negative social impacts among volunteers in an HIV Vaccine Efficacy Trial. J Acquir Immune Defic Syndr. 2007;47(3):1-7.
32. Newman PA, Duan N, Roberts KJ, et al. HIV vaccine trial participation among ethnic minority communities. J Acquir Immune Defic Syndr. 2006;41(2):210-217.
33. Priddy FH, Cheng AC, Salazar LF, Frew PM. Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US. Int J STD AIDS. 2006;17(2):99-102.
34. US Census Bureau. USA State and County QuickFacts. 2010. Available from: http://quickfacts.census.gov/qfd/states/13/1304000.html. Accessed Apr 21, 2010.
35. Hennessy M, MacQueen K, McKirnan D, et al. A factorial survey study to assess the acceptability of HIV vaccine trial designs. Control Clin Trials. 1996;17:209-220.
36. Ajzen I, Fishbein M. Understanding Attitudes and Predicting Social Behavior. Upper Saddle River, NJ: Prentice-Hall, Inc; 1980.
37. Albarracin D, Wyers RS. The cognitive impact of past behavior: influences on beliefs, attitudes, and future behavioral decisions. J Pers Soc Psychol. 2000;79(1):5-22.
38. Halpern SD, Metzger DS, Berlin JA, Ubel PA. Who will enroll? Predicting participation in a phase II AIDS vaccine trial. J Acquir Immune Defic Syndr. 2001;27(3):281-288.